UBS Warburg Remains Upbeat on Medtronic

Analyst David Lothson says the stock looks cheap again

Medtronic (MDT ) posted $0.30 Q4 EPS from operations on a 6% sales rise. UBS Warburg trimmed its estimate and lowered its price target on the medical device maker, but reiterated its strong buy rating on the shares.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.